| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2876490 | The Annals of Thoracic Surgery | 2011 | 8 Pages |
Abstract
The LCNEC has a high response rate to platinum-based neoadjuvant chemotherapy. Resected advanced-stage patients receiving combination neoadjuvant and (or) adjuvant chemotherapy may have a survival advantage. These therapies should be considered in resectable patients with LCNEC.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Inderpal S. MD, Akira MD, Mee Soo MD, Gabriel MD, PhD, Deborah MS, Camelia S. MD, Maria C. MD, Bernard J. MD, William D. MD, Valerie W. MD,